"10.1371_journal.pone.0103015","plos one","2014-09-02T00:00:00Z","Dongmin Gu; Shuhong Wang; Isere Kuiatse; Hua Wang; Jin He; Yun Dai; Richard J Jones; Chad C Bjorklund; Jing Yang; Steven Grant; Robert Z Orlowski","Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Hematology, Chinese PLA General Hospital, Beijing, China; Department of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States of America; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America","Conceived and designed the experiments: DG RZO. Performed the experiments: DG SW IK JH. Analyzed the data: DG RZO. Contributed reagents/materials/analysis tools: HW YD RJJ CCB JY SG. Wrote the paper: DG RZO.","Ascenta Therapeutics provided the MDM-2 inhibitor used in these studies. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","09","Dongmin Gu","DG",11,TRUE,2,4,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
